Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.63 |
| ▸ | APP | P05067 | 1/20 | 0.63 |
| ▸ | PYGL | P06737 | 9/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | TYR | P14679 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | JAK2 | O60674 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192123 | 1.00 | TTR (0.63) | TTRAPPPYGLPTPN1CA12 | |
| SCHEMBL14926723 | 0.87 | TTR (0.59) | TTRAPPPYGLPTPN1CA12 | |
| SCHEMBL30643757 | 0.85 | EPHX2 (0.66) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL1893824 | 0.85 | TTR (0.58) | TTRAPPPYGLPTPN1CA12 | |
| SCHEMBL15646549 | 0.85 | EPHX2 (0.70) | TTRAPPPTPN1CA12CA1 | |
| SCHEMBL23647676 | 0.85 | TTR (0.58) | TTRAPPPYGLPTPN1CA12 | |
| SCHEMBL1893825 | 0.85 | TTR (0.58) | TTRAPPPYGLPTPN1CA12 | |
| SCHEMBL23665770 | 0.85 | TTR (0.58) | TTRAPPPYGLPTPN1CA12 | |
| SCHEMBL23647677 | 0.85 | TTR (0.58) | TTRAPPPYGLPTPN1CA12 | |
| SCHEMBL2846167 | 0.85 | TTR (0.58) | TTRAPPPYGLPTPN1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2025-05-15 | — | — | US | disclosed |
| US-RE49686-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-10 | — | — | US | disclosed |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2022-07-21 | — | — | US | disclosed |
| US-RE48334-E1 | Nitrogen-containing heterocyclic compound and use of same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-12-01 | — | — | US | disclosed |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-11-05 | — | — | US | disclosed |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-08-18 | — | — | US | disclosed |
| US-9359340-B2 | Hydroxylated and methoxylated pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | GENENTECH, INC. | 2016-06-02 | — | — | US | disclosed |
| EP-2966065-A2 | HYDROXYLATED AND METHOXYLATED CYCLOPENTA [D] PYRIMIDINES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-01-13 | — | — | EP | disclosed |
| EP-0553081-A1 | PESTICIDES. | ROUSSEL UCLAF (FR) | 1993-08-04 | — | — | EP | disclosed |
| US-5089639-A | N-CYCLOALKYLALKYLAMINES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT AND THEIR SYNTHESIS INTERMEDIATES | JOUVEINAL S.A. (FR) | 1992-02-18 | — | — | US | disclosed |
| WO-1991016301-A1 | PESTICIDES | THE WELLCOME FOUNDATION LIMITED (GB) | 1991-10-31 | — | — | WO | disclosed |
| US-5034419-A | Psychological disorders or gastrointestinal disorders | L'OREAL (FR) | 1991-07-23 | — | — | US | disclosed |
| EP-0164852-B1 | 1-(SUBSTITUTED-ARYL)-DIHYDRO-1H-PYRROLIZINE-3,5-(2H,6H-)DIONES, A PROCESS FOR PRODUCING THE COMPOUNDS AND A PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0164853-B1 | (SUBSTITUTED-PHENYL)-5-OXO-2-PYRROLIDINEPROPANOIC ACIDS, A PROCESS FOR PRODUCING THE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS | WARNER-LAMBERT COMPANY (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4584313-A | TREATING SENILITY | WARNER-LAMBERT COMPANY (US) | 1986-04-22 | — | — | US | disclosed |
| EP-0164853-A1 | (substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids, a process for producing the compounds and pharmaceutical compositions comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
| EP-0164852-A1 | 1-(Substituted-aryl)-Dihydro-1H-pyrrolizine-3,5-(2H,6H-)diones, a process for producing the compounds and a pharmaceutical composition comprising the compounds | WARNER-LAMBERT COMPANY (US) | 1985-12-18 | — | — | EP | disclosed |
| US-4548947-A | 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia | WARNER-LAMBERT COMPANY (US) | 1985-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160235754-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT3 | TTR 3481/4885APP 4423/4885PYGL 631/4885 |
| US-20220226326-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | TTR 3685/4885APP 4505/4885PYGL 712/4885 |
| US-20180169099-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | TTR 3685/4885APP 4505/4885PYGL 712/4885 |
| US-20160152606-A9 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | TTR 3685/4885APP 4505/4885PYGL 712/4885 |
| US-20250152588-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | TTR 3685/4885APP 4505/4885PYGL 712/4885 |
| US-20200345735-A1 | HYDROXYLATED AND METHOXYLATED PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, AKT1S1 | TTR 3685/4885APP 4505/4885PYGL 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.